| BIOGEN INC. DL -,0005 | 221,100 / +0,50% |
| Fecha/Hora | 23.01. / 12:20 |
| Dif. / Dif.(%) | 1,100 / +0,50% |
| Bid | 221,100 |
| Ask | 222,250 |
| Apertura | 221,100 |
| Cierre del día anterior | 220,000 |
| Máxima sesión | 221,350 |
| Mínima sesión | 221,100 |
| Volumen [EUR] | - |
| Volumen [Unidades] | |
| Fijación de precios | 10 |
| ISIN | US09062X1037 |
| Símbolo | IDP |
| Bolsa | Lang & Schwarz |
| Tipo | Stock |
Otras Bolsas
| Bolsa | Último | Volumen | |
|---|---|---|---|
| Lang & Schwa.. | 221,100 |  |
|
| NASDAQ | 269,4400 | |
691.169 |
| IEX | 269,37 | |
36.610 |
| Cboe US | 269,57 | |
24.969 |
| London Inter.. | 270,23 | |
1.739 |
| Xetra | 221,10 | |
1.633 |
| TradeGate | 221,600 | |
1.166 |
| Mexico | 5.375,00 | |
129 |
| Stuttgart | 220,100 | |
115 |
| Frankfurt | 220,9500 | |
68 |
| Vienna Globa.. | 221,15 | |
51 |
| München | 222,10 | |
10 |
| gettex | 221,500 | |
5 |
| Hamburg | 220,60 | |
0 |
| Düsseldorf | 221,65 | |
0 |
| Berlin | 222,10 | |
0 |
| Hannover | 220,60 | |
0 |
Noticias
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
11.01.2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
08.01.2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
21.12.2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
17.12.2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
10.12.2020 / 04:30 - GlobeNewswire
Tiempo real